Watanabe, M.; Ieguchi, K.; Shimizu, T.; Ohkuma, R.; Suzuki, R.; Mura, E.; Iriguchi, N.; Ishiguro, T.; Hirasawa, Y.; Ikeda, G.;
et al. Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study. Cancers 2025, 17, 2384.
https://doi.org/10.3390/cancers17142384
AMA Style
Watanabe M, Ieguchi K, Shimizu T, Ohkuma R, Suzuki R, Mura E, Iriguchi N, Ishiguro T, Hirasawa Y, Ikeda G,
et al. Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study. Cancers. 2025; 17(14):2384.
https://doi.org/10.3390/cancers17142384
Chicago/Turabian Style
Watanabe, Makoto, Katsuaki Ieguchi, Takashi Shimizu, Ryotaro Ohkuma, Risako Suzuki, Emiko Mura, Nana Iriguchi, Tomoyuki Ishiguro, Yuya Hirasawa, Go Ikeda,
and et al. 2025. "Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study" Cancers 17, no. 14: 2384.
https://doi.org/10.3390/cancers17142384
APA Style
Watanabe, M., Ieguchi, K., Shimizu, T., Ohkuma, R., Suzuki, R., Mura, E., Iriguchi, N., Ishiguro, T., Hirasawa, Y., Ikeda, G., Shimokawa, M., Ariizumi, H., Yoshimura, K., Horiike, A., Tsunoda, T., Tsuji, M., Kobayashi, S., Oguchi, T., Kiuchi, Y.,
& Wada, S.
(2025). Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study. Cancers, 17(14), 2384.
https://doi.org/10.3390/cancers17142384
